<DOC>
	<DOCNO>NCT00598793</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial compare biphasic insulin aspart 30 plus metformin standard injection regimen standard dose insulin glargine plus metformin blood glucose control subject type 2 diabetes insulin naive fail OAD therapy .</brief_summary>
	<brief_title>Biphasic Insulin Aspart 30 Type 2 Diabetes Failing OAD Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Insulin naive Type 2 diabetes Currently treat OADs alone combine treatment least 3 month BMI 40 kg/m2 body weight 125 kg HbA1c great equal 8 % Inability tolerate metformin contradiction use Pregnant , breastfeed intention become pregnant Allergy trial product Inability unwillingness perform SMBG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>